BRPI0905952A2 - Composto e sais do mesmo e compição farmacêutica - Google Patents
Composto e sais do mesmo e compição farmacêuticaInfo
- Publication number
- BRPI0905952A2 BRPI0905952A2 BRPI0905952-0A BRPI0905952A BRPI0905952A2 BR PI0905952 A2 BRPI0905952 A2 BR PI0905952A2 BR PI0905952 A BRPI0905952 A BR PI0905952A BR PI0905952 A2 BRPI0905952 A2 BR PI0905952A2
- Authority
- BR
- Brazil
- Prior art keywords
- salts
- compound
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2600108P | 2008-02-04 | 2008-02-04 | |
US5120008P | 2008-05-07 | 2008-05-07 | |
PCT/US2009/033077 WO2009100130A1 (en) | 2008-02-04 | 2009-02-04 | Ampk modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0905952A2 true BRPI0905952A2 (pt) | 2015-06-30 |
Family
ID=40952443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0905952-0A BRPI0905952A2 (pt) | 2008-02-04 | 2009-02-04 | Composto e sais do mesmo e compição farmacêutica |
Country Status (16)
Country | Link |
---|---|
US (3) | US8273744B2 (pt) |
EP (1) | EP2240016A4 (pt) |
JP (2) | JP5525456B2 (pt) |
KR (1) | KR20100115789A (pt) |
CN (1) | CN101959404B (pt) |
AU (1) | AU2009212462B2 (pt) |
BR (1) | BRPI0905952A2 (pt) |
CA (1) | CA2714181C (pt) |
EA (1) | EA019309B1 (pt) |
IL (1) | IL207234A (pt) |
MX (1) | MX2010008376A (pt) |
MY (1) | MY158994A (pt) |
NZ (1) | NZ587165A (pt) |
UA (1) | UA106037C2 (pt) |
WO (1) | WO2009100130A1 (pt) |
ZA (1) | ZA201005600B (pt) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070077310A1 (en) * | 2005-10-03 | 2007-04-05 | University Of Tennessee Research Foundation | Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species |
PT3184526T (pt) | 2005-12-13 | 2018-12-19 | Incyte Holdings Corp | Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus |
US20080312259A1 (en) | 2007-06-13 | 2008-12-18 | Incyte Corporation | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE |
US8273744B2 (en) * | 2008-02-04 | 2012-09-25 | Mercury Therapeutics, Inc. | AMPK modulators |
BRPI0910439B8 (pt) | 2008-04-11 | 2021-05-25 | Merck Patent Gmbh | derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos |
AU2009296820B2 (en) | 2008-09-26 | 2014-03-20 | Merck Sharp & Dohme Llc | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
EP2352374B1 (en) | 2008-10-29 | 2014-09-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CN106967070A (zh) | 2009-05-22 | 2017-07-21 | 因塞特控股公司 | 作为jak抑制剂的化合物 |
ES2487542T3 (es) | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
GB0915892D0 (en) * | 2009-09-10 | 2009-10-14 | Smithkline Beecham Corp | Compounds |
WO2011032320A1 (en) * | 2009-09-21 | 2011-03-24 | F. Hoffmann-La Roche Ag | Novel alkene oxindole derivatives |
ES2663351T3 (es) | 2009-11-17 | 2018-04-12 | Novartis Ag | Derivados de aril-piridina como inhibidores de la aldosterona sintasa |
CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
TWI766281B (zh) | 2010-03-10 | 2022-06-01 | 美商英塞特控股公司 | 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物 |
PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Npy y5受容体拮抗作用を有するヘテロ環誘導体 |
EP2617722B1 (en) * | 2010-09-10 | 2016-03-23 | Shionogi & Co., Ltd. | Hetero ring-fused imidazole derivative having ampk activating effect |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
US9005909B2 (en) | 2011-01-06 | 2015-04-14 | Rigel Pharmaceuticals, Inc. | Whole blood assay for measuring AMPK activation |
CN103328449A (zh) * | 2011-01-26 | 2013-09-25 | 霍夫曼-拉罗奇有限公司 | 新的四氢喹啉衍生物 |
US8809369B2 (en) * | 2011-01-26 | 2014-08-19 | Hoffmann-La Roche Inc. | Tetrahydroquinoline derivatives |
KR101668514B1 (ko) * | 2011-02-25 | 2016-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체 |
CN103517896B (zh) * | 2011-03-07 | 2016-09-21 | 葛兰素史密斯克莱有限责任公司 | 喹啉酮衍生物 |
US20130345243A1 (en) * | 2011-03-07 | 2013-12-26 | Glaxosmithkline Llc | 1h-pyrollo[3,2-d]pyrimidinedione derivatives |
EA201490042A1 (ru) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak |
KR20140040801A (ko) * | 2011-07-15 | 2014-04-03 | 시오노기세야쿠 가부시키가이샤 | Ampk 활성화 작용을 갖는 아자벤즈이미다졸 유도체 |
EP3466418A1 (en) | 2011-07-15 | 2019-04-10 | NuSirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
US8889730B2 (en) * | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
TWI449702B (zh) * | 2012-07-11 | 2014-08-21 | Merck Sharp & Dohme | 作為抗糖尿病劑之新穎環氮雜苯并咪唑衍生物 |
BR112015010947A2 (pt) | 2012-11-13 | 2018-06-05 | Nusirt Sciences Inc | composições e métodos para aumentar o metabolismo energético. |
SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
EP2769974A1 (en) * | 2013-02-21 | 2014-08-27 | Debiopharm S.A. | Novel AMPK activator |
HUE057262T2 (hu) | 2013-03-06 | 2022-04-28 | Incyte Holdings Corp | Eljárás és köztitermékek JAK inhibitor elõállítására |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
BR112015023310A2 (pt) | 2013-03-15 | 2017-07-18 | Nusirt Sciences Inc | composições, métodos e kits para redução de níveis lipídicos |
CA2905242C (en) * | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
WO2014175330A1 (ja) * | 2013-04-24 | 2014-10-30 | 塩野義製薬株式会社 | Ampk活性化作用を有する5-オキシベンズイミダゾールおよび5-オキシアザベンズイミダゾール誘導体 |
US20160368870A1 (en) * | 2013-06-20 | 2016-12-22 | Boehringer Ingelheim International Gmbh | Olefin substituted oxindoles having ampk activity |
US9655854B2 (en) | 2013-08-07 | 2017-05-23 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
WO2015131152A1 (en) | 2014-02-27 | 2015-09-03 | Nusirt Sciences Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
JP6579550B2 (ja) * | 2014-08-27 | 2019-09-25 | 塩野義製薬株式会社 | Ampk活性化作用を有するアザインドール誘導体 |
JPWO2016068099A1 (ja) | 2014-10-28 | 2017-08-10 | 塩野義製薬株式会社 | Ampk活性化作用を有する複素環誘導体 |
CN104774172B (zh) * | 2015-04-08 | 2017-03-22 | 河南师范大学 | 一种3‑氰基吲哚类化合物的合成方法 |
CN107708419B (zh) * | 2015-05-26 | 2021-08-27 | 高雄医学大学 | 具抑制细菌葡萄糖醛酸酶活性的吡唑并[4,3-c]喹啉衍生物 |
WO2017146186A1 (ja) | 2016-02-26 | 2017-08-31 | 塩野義製薬株式会社 | Ampk活性化作用を有する5-フェニルアザインドール誘導体 |
EP3459949A4 (en) | 2016-05-20 | 2020-04-08 | Shionogi & Co., Ltd | 5-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE WITH AMPK ACTIVATION EFFECT |
AU2017322427B2 (en) | 2016-09-09 | 2021-12-23 | Incyte Corporation | Pyrazolopyridine derivatives as HPK1 modulators and uses thereof for the treatment of cancer |
TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
CN107556309B (zh) * | 2017-09-11 | 2020-12-01 | 浙江永宁药业股份有限公司 | 多取代四氢萘啶类化合物的药物用途及其制备方法 |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
CN112105608B (zh) | 2018-01-30 | 2023-07-14 | 因赛特公司 | 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法 |
EP3749669B1 (en) | 2018-02-06 | 2023-03-08 | Ideaya Biosciences, Inc. | Ahr modulators |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
KR20200133747A (ko) | 2018-02-20 | 2020-11-30 | 인사이트 코포레이션 | 암을 치료하기 위한 hpk1 억제제로서의 n-(페닐)-2-(페닐)피리미딘-4-카복스아미드 유도체 및 관련 화합물 |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
HUE057970T2 (hu) | 2018-03-08 | 2022-06-28 | Incyte Corp | Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok |
JP6557436B1 (ja) | 2018-03-12 | 2019-08-07 | アッヴィ・インコーポレイテッド | チロシンキナーゼ2媒介性シグナル伝達の阻害剤 |
AU2019245420A1 (en) | 2018-03-30 | 2020-11-12 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
CA3107170A1 (en) * | 2018-08-06 | 2020-03-12 | Skylark Bioscience Llc | Amp-activated protein kinase activating compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
US11396502B2 (en) | 2018-11-13 | 2022-07-26 | Incyte Corporation | Substituted heterocyclic derivatives as PI3K inhibitors |
US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
WO2020102198A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
EP4221700A1 (en) | 2020-09-30 | 2023-08-09 | Bioverativ Therapeutics Inc. | Ampk activators and methods of use thereof |
CN112342216B (zh) * | 2020-11-13 | 2021-07-23 | 中国人民解放军军事科学院军事医学研究院 | 用于提高CHO细胞的表达效率的CRISPR-Cas13d系统以及重组CHO细胞 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5245044A (en) * | 1991-10-30 | 1993-09-14 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Di(hydroxyphenyl)-benzimidazole monomers |
US7101915B1 (en) * | 1996-07-31 | 2006-09-05 | Shionogi & Co., Ltd. | P-terphenyl compounds |
US6232322B1 (en) * | 1998-05-12 | 2001-05-15 | American Home Products Corporation | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
JP2000204091A (ja) * | 1999-01-13 | 2000-07-25 | Nippon Suisan Kaisha Ltd | 新規ベンゾジオキソ―ル誘導体 |
US6265403B1 (en) * | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
EP1319001A1 (en) | 2000-09-22 | 2003-06-18 | Smithkline Beecham Plc | Pyrazolopyridines and pyrazolopyridazines as antidiabetics |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
US20030203959A1 (en) * | 2002-03-04 | 2003-10-30 | 4Sc Ag | Novel modulators of potassium channels |
UA80453C2 (en) * | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
CA2510298A1 (en) | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Acyclic pyrazole compounds |
AU2004236249A1 (en) | 2003-04-30 | 2004-11-18 | The Institutes Of Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1B |
US7119205B2 (en) * | 2003-05-16 | 2006-10-10 | Abbott Laboratories | Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
GB0400895D0 (en) * | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
EP1780202B1 (en) | 2004-08-04 | 2013-02-27 | Meiji Seika Pharma Co., Ltd. | Quinoline derivative and insecticide containing same as active constituent |
GB0424308D0 (en) * | 2004-11-03 | 2004-12-01 | Qinetiq Ltd | Compounds for use in liquid crystal devices |
JP4954083B2 (ja) * | 2004-11-18 | 2012-06-13 | シンタ ファーマスーティカルズ コーポレイション | Hsp90活性を調節するトリアゾール化合物 |
AU2005307735A1 (en) * | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Substituted amino acids as protein Tyrosine phosphatase inhibitors |
PL1861387T3 (pl) | 2005-01-28 | 2014-08-29 | Dae Woong Pharma | Pochodne benzoimidazolu i ich kompozycje farmaceutyczne |
WO2007019397A2 (en) | 2005-08-05 | 2007-02-15 | Genelabs Technologies, Inc. | 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus |
CA2618724A1 (en) * | 2005-08-18 | 2007-02-22 | Synta Pharmaceuticals Corp. | Imidazole compounds that modulate hsp90 activity |
WO2007056155A1 (en) * | 2005-11-03 | 2007-05-18 | Chembridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
ES2684821T3 (es) * | 2005-12-29 | 2018-10-04 | Lexicon Pharmaceuticals, Inc. | Derivados de aminoácidos multicíclicos y métodos de su uso |
US20070208053A1 (en) * | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
JP5112083B2 (ja) | 2006-02-03 | 2013-01-09 | Meiji Seikaファルマ株式会社 | 新規キノリン誘導体およびこれを有効成分として含有する農園芸用殺菌剤 |
US20070191371A1 (en) | 2006-02-14 | 2007-08-16 | Kalypsys, Inc. | Heterocyclic modulators of ppar |
WO2007139967A2 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
WO2008007900A1 (en) | 2006-07-11 | 2008-01-17 | Daewoong Pharmaceutical Co., Ltd. | Novel biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same |
CN101490016A (zh) | 2006-07-28 | 2009-07-22 | 诺瓦提斯公司 | 作为脂激酶抑制剂的2,4-取代的喹唑啉 |
US8273744B2 (en) * | 2008-02-04 | 2012-09-25 | Mercury Therapeutics, Inc. | AMPK modulators |
-
2009
- 2009-02-04 US US12/365,671 patent/US8273744B2/en not_active Expired - Fee Related
- 2009-02-04 CN CN200980107550.0A patent/CN101959404B/zh not_active Expired - Fee Related
- 2009-02-04 EP EP09707948A patent/EP2240016A4/en not_active Withdrawn
- 2009-02-04 KR KR1020107019375A patent/KR20100115789A/ko not_active Application Discontinuation
- 2009-02-04 AU AU2009212462A patent/AU2009212462B2/en not_active Ceased
- 2009-02-04 BR BRPI0905952-0A patent/BRPI0905952A2/pt not_active IP Right Cessation
- 2009-02-04 MX MX2010008376A patent/MX2010008376A/es active IP Right Grant
- 2009-02-04 EA EA201001257A patent/EA019309B1/ru not_active IP Right Cessation
- 2009-02-04 MY MYPI2010003586A patent/MY158994A/en unknown
- 2009-02-04 UA UAA201010653A patent/UA106037C2/uk unknown
- 2009-02-04 JP JP2010545273A patent/JP5525456B2/ja not_active Expired - Fee Related
- 2009-02-04 WO PCT/US2009/033077 patent/WO2009100130A1/en active Application Filing
- 2009-02-04 CA CA2714181A patent/CA2714181C/en not_active Expired - Fee Related
- 2009-02-04 NZ NZ587165A patent/NZ587165A/en not_active IP Right Cessation
-
2010
- 2010-07-26 IL IL207234A patent/IL207234A/en not_active IP Right Cessation
- 2010-08-05 ZA ZA2010/05600A patent/ZA201005600B/en unknown
-
2012
- 2012-08-09 US US13/571,218 patent/US8980895B2/en not_active Expired - Fee Related
-
2013
- 2013-09-17 JP JP2013191655A patent/JP2014028828A/ja not_active Withdrawn
-
2015
- 2015-02-19 US US14/625,925 patent/US20150266892A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA019309B1 (ru) | 2014-02-28 |
CN101959404B (zh) | 2015-12-02 |
EP2240016A4 (en) | 2011-11-16 |
US20150266892A1 (en) | 2015-09-24 |
CA2714181C (en) | 2013-12-24 |
CA2714181A1 (en) | 2009-08-13 |
US20100009992A1 (en) | 2010-01-14 |
EP2240016A1 (en) | 2010-10-20 |
EA201001257A1 (ru) | 2011-04-29 |
AU2009212462A1 (en) | 2009-08-13 |
KR20100115789A (ko) | 2010-10-28 |
AU2009212462B2 (en) | 2012-09-13 |
US20120302576A1 (en) | 2012-11-29 |
US8980895B2 (en) | 2015-03-17 |
IL207234A (en) | 2016-06-30 |
CN101959404A (zh) | 2011-01-26 |
JP2014028828A (ja) | 2014-02-13 |
MX2010008376A (es) | 2011-02-22 |
MY158994A (en) | 2016-11-30 |
US8273744B2 (en) | 2012-09-25 |
JP5525456B2 (ja) | 2014-06-18 |
IL207234A0 (en) | 2010-12-30 |
JP2011511008A (ja) | 2011-04-07 |
UA106037C2 (uk) | 2014-07-25 |
WO2009100130A1 (en) | 2009-08-13 |
ZA201005600B (en) | 2016-09-28 |
NZ587165A (en) | 2012-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0905952A2 (pt) | Composto e sais do mesmo e compição farmacêutica | |
NL300891I2 (nl) | Lotilaner en zouten daarvan | |
LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
LTPA2018005I1 (lt) | Farmacinė kompozicija | |
SMT201600259B (it) | Composizioni farmaceutiche antibatteriche | |
BRPI0906962A2 (pt) | Composto, e, composição farmacêutica | |
BRPI0906556A2 (pt) | Composto, e, composição farmacêutica | |
BRPI0721651A2 (pt) | Composição farmacêutica | |
BRPI0922466A2 (pt) | sais | |
DK3345625T3 (da) | Farmaceutisk sammensætning og indgivelser deraf | |
DK3097925T3 (da) | Farmaceutisk sammensætning | |
BRPI0917681A2 (pt) | Composto, e, composição farmacêutica | |
BRPI1004940A2 (pt) | composição farmacêutica | |
DK3492069T3 (da) | Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid | |
DK2285413T3 (da) | Farmaceutisk sammensætning | |
DK2120884T3 (da) | Farmaceutisk sammensætning | |
BRPI0819232A2 (pt) | composto heterocíclico e composição farmacêutica do mesmo | |
BRPI1015939A2 (pt) | composição farmacêutica | |
BRPI0921313A2 (pt) | composição farmaucêutica | |
BRPI0921654A2 (pt) | formulação farmacêutica | |
BR112012000831A2 (pt) | compostos, composições farmacêuticas e métodos relacionados | |
DK2209464T3 (da) | Farmaceutisk sammensætning mod malaria | |
BRPI0820198A2 (pt) | composições farmacêuticas | |
BRPI0912118A2 (pt) | composto, composição farmacêutica, e, intermediário sintético | |
BRPI0914182A2 (pt) | composto, e, composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |